Share Twitter LinkedIn Facebook Email James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating the bi-specific CAR-T cell therapy.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read